IL302223A - Intranasal administration of suramin for treating nervous system disorders - Google Patents

Info

Publication number

IL302223A

IL302223A IL302223A IL30222323A IL302223A IL 302223 A IL302223 A IL 302223A IL 302223 A IL302223 A IL 302223A IL 30222323 A IL30222323 A IL 30222323A IL 302223 A IL302223 A IL 302223A

Authority

IL

Israel

Prior art keywords

suramin

mice

nervous system

disorder

patient

Prior art date

2020-10-22

Links

• Espacenet
• Global Dossier
• Discuss

• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 title claims description 322
• 229960005314 suramin Drugs 0.000 title claims description 312
• 208000012902 Nervous system disease Diseases 0.000 title claims description 65
• 238000011282 treatment Methods 0.000 title description 88
• 239000000203 mixture Substances 0.000 claims description 242
• 238000000034 method Methods 0.000 claims description 167
• 238000012360 testing method Methods 0.000 claims description 118
• 239000003814 drug Substances 0.000 claims description 85
• 230000009261 transgenic effect Effects 0.000 claims description 77
• 208000029560 autism spectrum disease Diseases 0.000 claims description 67
• 208000024891 symptom Diseases 0.000 claims description 66
• 230000003442 weekly effect Effects 0.000 claims description 59
• 208000001914 Fragile X syndrome Diseases 0.000 claims description 51
• 201000003415 fragile X-associated tremor/ataxia syndrome Diseases 0.000 claims description 45
• 230000003542 behavioural effect Effects 0.000 claims description 44
• -1 alkali metal salt Chemical class 0.000 claims description 43
• 210000005013 brain tissue Anatomy 0.000 claims description 42
• 150000003839 salts Chemical class 0.000 claims description 38
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 36
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 36
• 230000003997 social interaction Effects 0.000 claims description 36
• 208000035475 disorder Diseases 0.000 claims description 32
• 229940002612 prodrug Drugs 0.000 claims description 32
• 239000000651 prodrug Substances 0.000 claims description 32
• 208000020706 Autistic disease Diseases 0.000 claims description 31
• 206010057244 Post viral fatigue syndrome Diseases 0.000 claims description 28
• 150000002148 esters Chemical class 0.000 claims description 28
• 208000009575 Angelman syndrome Diseases 0.000 claims description 27
• 230000036470 plasma concentration Effects 0.000 claims description 27
• 239000012453 solvate Substances 0.000 claims description 26
• 208000019901 Anxiety disease Diseases 0.000 claims description 25
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 25
• 208000016620 Tourette disease Diseases 0.000 claims description 25
• 230000015654 memory Effects 0.000 claims description 25
• 210000002381 plasma Anatomy 0.000 claims description 25
• 230000006872 improvement Effects 0.000 claims description 22
• 230000013016 learning Effects 0.000 claims description 22
• 208000025721 COVID-19 Diseases 0.000 claims description 21
• 230000007774 longterm Effects 0.000 claims description 21
• 210000001519 tissue Anatomy 0.000 claims description 21
• 210000003169 central nervous system Anatomy 0.000 claims description 20
• 230000035515 penetration Effects 0.000 claims description 19
• 230000006742 locomotor activity Effects 0.000 claims description 18
• 230000031836 visual learning Effects 0.000 claims description 18
• 208000016604 Lyme disease Diseases 0.000 claims description 16
• 230000007529 anxiety like behavior Effects 0.000 claims description 16
• 208000015114 central nervous system disease Diseases 0.000 claims description 16
• 230000006886 spatial memory Effects 0.000 claims description 16
• 208000018737 Parkinson disease Diseases 0.000 claims description 15
• 241000701022 Cytomegalovirus Species 0.000 claims description 14
• 241000701041 Human betaherpesvirus 7 Species 0.000 claims description 14
• 241000701027 Human herpesvirus 6 Species 0.000 claims description 14
• 238000012347 Morris Water Maze Methods 0.000 claims description 14
• 241000700584 Simplexvirus Species 0.000 claims description 14
• 241000700605 Viruses Species 0.000 claims description 14
• 239000008194 pharmaceutical composition Substances 0.000 claims description 14
• 230000003989 repetitive behavior Effects 0.000 claims description 14
• 208000013406 repetitive behavior Diseases 0.000 claims description 14
• 208000022379 autosomal dominant Opitz G/BBB syndrome Diseases 0.000 claims description 13
• 239000007922 nasal spray Substances 0.000 claims description 13
• CJUDSKIRZCSXJA-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 CJUDSKIRZCSXJA-UHFFFAOYSA-M 0.000 claims description 13
• 229940097496 nasal spray Drugs 0.000 claims description 12
• 208000013403 hyperactivity Diseases 0.000 claims description 11
• 238000010171 animal model Methods 0.000 claims description 9
• 238000011302 passive avoidance test Methods 0.000 claims description 9
• 238000000638 solvent extraction Methods 0.000 claims description 9
• 206010022998 Irritability Diseases 0.000 claims description 8
• 230000006400 anxiety behaviour Effects 0.000 claims description 8
• 210000000653 nervous system Anatomy 0.000 claims description 8
• 208000011580 syndromic disease Diseases 0.000 claims description 8
• WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 8
• 150000003863 ammonium salts Chemical class 0.000 claims description 7
• 206010011469 Crying Diseases 0.000 claims description 6
• 206010024264 Lethargy Diseases 0.000 claims description 6
• 206010041243 Social avoidant behaviour Diseases 0.000 claims description 6
• 208000035056 Tick-Borne disease Diseases 0.000 claims description 6
• 238000013019 agitation Methods 0.000 claims description 6
• 238000010172 mouse model Methods 0.000 claims description 6
• 230000004006 stereotypic behavior Effects 0.000 claims description 6
• 208000016523 tick-borne infectious disease Diseases 0.000 claims description 6
• 239000012530 fluid Substances 0.000 claims description 5
• 230000003232 mucoadhesive effect Effects 0.000 claims description 5
• 208000036640 Asperger disease Diseases 0.000 claims description 4
• 201000006062 Asperger syndrome Diseases 0.000 claims description 4
• 229910052783 alkali metal Inorganic materials 0.000 claims description 4
• 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
• 208000024825 childhood disintegrative disease Diseases 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 159000000000 sodium salts Chemical group 0.000 claims description 2
• 241000699670 Mus sp. Species 0.000 description 221
• 238000009472 formulation Methods 0.000 description 98
• 238000007912 intraperitoneal administration Methods 0.000 description 88
• 239000007921 spray Substances 0.000 description 88
• 241000699666 Mus <mouse, genus> Species 0.000 description 82
• 229940079593 drug Drugs 0.000 description 76
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
• 239000003795 chemical substances by application Substances 0.000 description 43
• 230000000694 effects Effects 0.000 description 41
• 239000011780 sodium chloride Substances 0.000 description 41
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
• 241001465754 Metazoa Species 0.000 description 34
• 238000002347 injection Methods 0.000 description 30
• 239000007924 injection Substances 0.000 description 30
• 229920000858 Cyclodextrin Polymers 0.000 description 28
• 206010003805 Autism Diseases 0.000 description 27
• 230000006399 behavior Effects 0.000 description 24
• 238000012549 training Methods 0.000 description 23
• 238000012544 monitoring process Methods 0.000 description 22
• 241000283984 Rodentia Species 0.000 description 20
• 208000028173 post-traumatic stress disease Diseases 0.000 description 19
• 101150082209 Fmr1 gene Proteins 0.000 description 17
• 238000010521 absorption reaction Methods 0.000 description 16
• XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 16
• 239000003623 enhancer Substances 0.000 description 16
• 230000001965 increasing effect Effects 0.000 description 16
• 238000002156 mixing Methods 0.000 description 16
• 239000000523 sample Substances 0.000 description 16
• YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 14
• 230000036506 anxiety Effects 0.000 description 14
• 238000009227 behaviour therapy Methods 0.000 description 14
• 230000001149 cognitive effect Effects 0.000 description 14
• 150000001875 compounds Chemical class 0.000 description 14
• 239000002270 dispersing agent Substances 0.000 description 14
• 239000004615 ingredient Substances 0.000 description 14
• 208000029726 Neurodevelopmental disease Diseases 0.000 description 13
• 230000000384 rearing effect Effects 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 210000004556 brain Anatomy 0.000 description 12
• 230000006735 deficit Effects 0.000 description 12
• 238000002483 medication Methods 0.000 description 12
• 238000011160 research Methods 0.000 description 12
• 229960004853 betadex Drugs 0.000 description 11
• 239000000499 gel Substances 0.000 description 11
• 230000035939 shock Effects 0.000 description 11
• 239000002562 thickening agent Substances 0.000 description 11
• 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 10
• 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 230000008499 blood brain barrier function Effects 0.000 description 10
• 125000005456 glyceride group Chemical group 0.000 description 10
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 239000000546 pharmaceutical excipient Substances 0.000 description 10
• 108090000623 proteins and genes Proteins 0.000 description 10
• 206010010904 Convulsion Diseases 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 210000001218 blood-brain barrier Anatomy 0.000 description 9
• 238000011156 evaluation Methods 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 230000033001 locomotion Effects 0.000 description 9
• 239000003755 preservative agent Substances 0.000 description 9
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 9
• 239000004094 surface-active agent Substances 0.000 description 9
• 230000009885 systemic effect Effects 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 8
• 238000011813 knockout mouse model Methods 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000011740 C57BL/6 mouse Methods 0.000 description 7
• 206010052804 Drug tolerance Diseases 0.000 description 7
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
• 230000002159 abnormal effect Effects 0.000 description 7
• 239000000443 aerosol Substances 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 230000026781 habituation Effects 0.000 description 7
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
• 210000004379 membrane Anatomy 0.000 description 7
• 239000003961 penetration enhancing agent Substances 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 208000019116 sleep disease Diseases 0.000 description 7
• 229920002148 Gellan gum Polymers 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 125000002252 acyl group Chemical group 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 230000036541 health Effects 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 210000002850 nasal mucosa Anatomy 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000002335 preservative effect Effects 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• 230000006403 short-term memory Effects 0.000 description 6
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 6
• 229920001661 Chitosan Polymers 0.000 description 5
• 241000970811 Dictyoglomi Species 0.000 description 5
• 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 5
• 241000305071 Enterobacterales Species 0.000 description 5
• 241000008920 Gammacoronavirus Species 0.000 description 5
• 102000000033 Purinergic Receptors Human genes 0.000 description 5
• 108010080192 Purinergic Receptors Proteins 0.000 description 5
• 206010044565 Tremor Diseases 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 210000003128 head Anatomy 0.000 description 5
• 239000003906 humectant Substances 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 210000003928 nasal cavity Anatomy 0.000 description 5
• 230000003188 neurobehavioral effect Effects 0.000 description 5
• 210000001331 nose Anatomy 0.000 description 5
• 208000020016 psychiatric disease Diseases 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
• 241000243985 Onchocerca volvulus Species 0.000 description 4
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 229960000686 benzalkonium chloride Drugs 0.000 description 4
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 238000004891 communication Methods 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 230000001186 cumulative effect Effects 0.000 description 4
• 229940097362 cyclodextrins Drugs 0.000 description 4
• 210000003520 dendritic spine Anatomy 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
• 238000001647 drug administration Methods 0.000 description 4
• 239000003974 emollient agent Substances 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 230000001747 exhibiting effect Effects 0.000 description 4
• 239000006260 foam Substances 0.000 description 4
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 229920000609 methyl cellulose Polymers 0.000 description 4
• 235000010981 methylcellulose Nutrition 0.000 description 4
• 239000001923 methylcellulose Substances 0.000 description 4
• 229960002900 methylcellulose Drugs 0.000 description 4
• 239000002480 mineral oil Substances 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
• 208000022925 sleep disturbance Diseases 0.000 description 4
• 230000011273 social behavior Effects 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• VAPNKLKDKUDFHK-UHFFFAOYSA-H suramin sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)C)C=CC=3)C)=CC=C(S([O-])(=O)=O)C2=C1 VAPNKLKDKUDFHK-UHFFFAOYSA-H 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 230000000472 traumatic effect Effects 0.000 description 4
• 201000002311 trypanosomiasis Diseases 0.000 description 4
• 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 3
• WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 3
• BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 3
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 3
• RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
• 208000000044 Amnesia Diseases 0.000 description 3
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 3
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 201000006347 Intellectual Disability Diseases 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• 235000019482 Palm oil Nutrition 0.000 description 3
• 239000004372 Polyvinyl alcohol Substances 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 229920002125 Sokalan® Polymers 0.000 description 3
• 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 3
• 229930003427 Vitamin E Natural products 0.000 description 3
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
• 150000005215 alkyl ethers Chemical class 0.000 description 3
• 235000010407 ammonium alginate Nutrition 0.000 description 3
• 239000000728 ammonium alginate Substances 0.000 description 3
• KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 230000003078 antioxidant effect Effects 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
• 230000037007 arousal Effects 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 229960001631 carbomer Drugs 0.000 description 3
• 239000004359 castor oil Substances 0.000 description 3
• 235000019438 castor oil Nutrition 0.000 description 3
• 210000004027 cell Anatomy 0.000 description 3
• 229940082500 cetostearyl alcohol Drugs 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 208000010877 cognitive disease Diseases 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 238000007405 data analysis Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 238000001035 drying Methods 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 229960005309 estradiol Drugs 0.000 description 3
• 229930182833 estradiol Natural products 0.000 description 3
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
• UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 3
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 229960003943 hypromellose Drugs 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000006984 memory degeneration Effects 0.000 description 3
• 208000023060 memory loss Diseases 0.000 description 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
• 235000010446 mineral oil Nutrition 0.000 description 3
• RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
• 210000004877 mucosa Anatomy 0.000 description 3
• 229940043348 myristyl alcohol Drugs 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 239000002540 palm oil Substances 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000035699 permeability Effects 0.000 description 3
• 230000002085 persistent effect Effects 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 229920002451 polyvinyl alcohol Polymers 0.000 description 3
• 229940068984 polyvinyl alcohol Drugs 0.000 description 3
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 229940026235 propylene glycol monolaurate Drugs 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 230000003252 repetitive effect Effects 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 230000005476 size effect Effects 0.000 description 3
• 230000007958 sleep Effects 0.000 description 3
• 235000010265 sodium sulphite Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• 235000019165 vitamin E Nutrition 0.000 description 3
• 239000011709 vitamin E Substances 0.000 description 3
• 229940046009 vitamin E Drugs 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• 229920001285 xanthan gum Polymers 0.000 description 3
• 235000010493 xanthan gum Nutrition 0.000 description 3
• 239000000230 xanthan gum Substances 0.000 description 3
• 229940082509 xanthan gum Drugs 0.000 description 3
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
• 208000000230 African Trypanosomiasis Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 208000006820 Arthralgia Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 206010063659 Aversion Diseases 0.000 description 2
• 241000589969 Borreliella burgdorferi Species 0.000 description 2
• 241000195940 Bryophyta Species 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• 241001678559 COVID-19 virus Species 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 206010011224 Cough Diseases 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
• 208000035976 Developmental Disabilities Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
• 208000010201 Exanthema Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 2
• 241000238703 Ixodes scapularis Species 0.000 description 2
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
• 239000004166 Lanolin Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 208000013716 Motor tics Diseases 0.000 description 2
• 208000011644 Neurologic Gait disease Diseases 0.000 description 2
• 208000027089 Parkinsonian disease Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 208000013717 Phonic tics Diseases 0.000 description 2
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
• 229920000148 Polycarbophil calcium Polymers 0.000 description 2
• DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
• 229920002675 Polyoxyl Polymers 0.000 description 2
• 229920001214 Polysorbate 60 Polymers 0.000 description 2
• HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 2
• 206010037075 Protozoal infections Diseases 0.000 description 2
• 239000004373 Pullulan Substances 0.000 description 2
• 229920001218 Pullulan Polymers 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 208000008234 Tics Diseases 0.000 description 2
• 206010070863 Toxicity to various agents Diseases 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 210000001766 X chromosome Anatomy 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 229940045942 acetone sodium bisulfite Drugs 0.000 description 2
• 229960004308 acetylcysteine Drugs 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229940087168 alpha tocopherol Drugs 0.000 description 2
• 230000001773 anti-convulsant effect Effects 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 229960003965 antiepileptics Drugs 0.000 description 2
• 239000002249 anxiolytic agent Substances 0.000 description 2
• 230000000949 anxiolytic effect Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
• 239000003833 bile salt Substances 0.000 description 2
• 239000000227 bioadhesive Substances 0.000 description 2
• 239000007844 bleaching agent Substances 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 229910021538 borax Inorganic materials 0.000 description 2
• 230000004641 brain development Effects 0.000 description 2
• 210000000621 bronchi Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 235000010410 calcium alginate Nutrition 0.000 description 2
• 239000000648 calcium alginate Substances 0.000 description 2
• 229960002681 calcium alginate Drugs 0.000 description 2
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
• 239000001527 calcium lactate Substances 0.000 description 2
• 229960002401 calcium lactate Drugs 0.000 description 2
• 235000011086 calcium lactate Nutrition 0.000 description 2
• OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
• 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
• 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 229960002798 cetrimide Drugs 0.000 description 2
• 229960000541 cetyl alcohol Drugs 0.000 description 2
• 229940074979 cetyl palmitate Drugs 0.000 description 2
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
• YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
• 150000005829 chemical entities Chemical class 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 229940107161 cholesterol Drugs 0.000 description 2
• 230000003920 cognitive function Effects 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 230000003750 conditioning effect Effects 0.000 description 2
• 229940086555 cyclomethicone Drugs 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 201000005884 exanthem Diseases 0.000 description 2
• 230000021824 exploration behavior Effects 0.000 description 2
• 210000003722 extracellular fluid Anatomy 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 229940014259 gelatin Drugs 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 235000010492 gellan gum Nutrition 0.000 description 2
• 239000000216 gellan gum Substances 0.000 description 2
• 239000003349 gelling agent Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229940075507 glyceryl monostearate Drugs 0.000 description 2
• KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
• 229910000271 hectorite Inorganic materials 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
• 210000001320 hippocampus Anatomy 0.000 description 2
• 208000029080 human African trypanosomiasis Diseases 0.000 description 2
• 239000000017 hydrogel Substances 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 239000001341 hydroxy propyl starch Substances 0.000 description 2
• 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
• 229940072106 hydroxystearate Drugs 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 235000015110 jellies Nutrition 0.000 description 2
• 239000008274 jelly Substances 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 235000019388 lanolin Nutrition 0.000 description 2
• 229940039717 lanolin Drugs 0.000 description 2
• 229940099367 lanolin alcohols Drugs 0.000 description 2
• 150000002605 large molecules Chemical class 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 230000003137 locomotive effect Effects 0.000 description 2
• 208000027028 long COVID Diseases 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 206010025482 malaise Diseases 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
• 235000011929 mousse Nutrition 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 208000003177 ocular onchocerciasis Diseases 0.000 description 2
• 229940055577 oleyl alcohol Drugs 0.000 description 2
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
• 208000002042 onchocerciasis Diseases 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 208000035824 paresthesia Diseases 0.000 description 2
• 235000010987 pectin Nutrition 0.000 description 2
• 239000001814 pectin Substances 0.000 description 2
• 229920001277 pectin Polymers 0.000 description 2
• 238000013148 permeation assay Methods 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
• 229960000502 poloxamer Drugs 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229950005134 polycarbophil Drugs 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 235000010408 potassium alginate Nutrition 0.000 description 2
• 239000000737 potassium alginate Substances 0.000 description 2
• MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 2
• RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
• 229940043349 potassium metabisulfite Drugs 0.000 description 2
• 235000010263 potassium metabisulphite Nutrition 0.000 description 2
• FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 2
• 239000000770 propane-1,2-diol alginate Substances 0.000 description 2
• 235000019260 propionic acid Nutrition 0.000 description 2
• 229940095574 propionic acid Drugs 0.000 description 2
• 235000010388 propyl gallate Nutrition 0.000 description 2
• 239000000473 propyl gallate Substances 0.000 description 2
• 229940075579 propyl gallate Drugs 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• 235000019423 pullulan Nutrition 0.000 description 2
• 230000001696 purinergic effect Effects 0.000 description 2
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
• 206010037844 rash Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 229910000275 saponite Inorganic materials 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000035807 sensation Effects 0.000 description 2
• 235000019615 sensations Nutrition 0.000 description 2
• 231100000245 skin permeability Toxicity 0.000 description 2
• 201000002612 sleeping sickness Diseases 0.000 description 2
• 230000004036 social memory Effects 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
• 239000001540 sodium lactate Substances 0.000 description 2
• 235000011088 sodium lactate Nutrition 0.000 description 2
• 229940005581 sodium lactate Drugs 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 229940001584 sodium metabisulfite Drugs 0.000 description 2
• 235000010262 sodium metabisulphite Nutrition 0.000 description 2
• 229940001482 sodium sulfite Drugs 0.000 description 2
• 235000010339 sodium tetraborate Nutrition 0.000 description 2
• YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 2
• 239000008137 solubility enhancer Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229940044609 sulfur dioxide Drugs 0.000 description 2
• 235000010269 sulphur dioxide Nutrition 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
• 229940033663 thimerosal Drugs 0.000 description 2
• MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
• 229960000984 tocofersolan Drugs 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 229940093609 tricaprylin Drugs 0.000 description 2
• VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• 230000009184 walking Effects 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 235000004835 α-tocopherol Nutrition 0.000 description 2
• 239000002076 α-tocopherol Substances 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
• DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Polymers CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 1
• RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
• QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
• QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 241000238876 Acari Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
• 102000009346 Adenosine receptors Human genes 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 208000010470 Ageusia Diseases 0.000 description 1
• 206010001488 Aggression Diseases 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000004881 Amebiasis Diseases 0.000 description 1
• 206010001980 Amoebiasis Diseases 0.000 description 1
• 206010002653 Anosmia Diseases 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 241000233788 Arecaceae Species 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 206010003399 Arthropod bite Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 241000690120 Borrelia mayonii Species 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 235000013913 Ceratonia Nutrition 0.000 description 1
• 241001060815 Ceratonia Species 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
• UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
• 208000034657 Convalescence Diseases 0.000 description 1
• 208000001528 Coronaviridae Infections Diseases 0.000 description 1
• 206010050685 Cytokine storm Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010013082 Discomfort Diseases 0.000 description 1
• RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010062488 Erythema migrans Diseases 0.000 description 1
• IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 206010017062 Formication Diseases 0.000 description 1
• 229930194076 Germanin Natural products 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 206010020046 High arched palate Diseases 0.000 description 1
• 101100259947 Homo sapiens TBATA gene Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
• 206010021033 Hypomenorrhoea Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• 229920002774 Maltodextrin Polymers 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• 101100113065 Mus musculus Cfi gene Proteins 0.000 description 1
• 101100013186 Mus musculus Fmr1 gene Proteins 0.000 description 1
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 208000008457 Neurologic Manifestations Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 208000012202 Pervasive developmental disease Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• 206010035737 Pneumonia viral Diseases 0.000 description 1
• 229920001100 Polydextrose Polymers 0.000 description 1
• 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 1
• 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
• 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
• 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
• 241000588733 Pseudescherichia vulneris Species 0.000 description 1
• 102000002294 Purinergic P2X Receptors Human genes 0.000 description 1
• 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
• 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 1
• 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 1
• 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
• 206010062237 Renal impairment Diseases 0.000 description 1
• 206010038583 Repetitive speech Diseases 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 206010040026 Sensory disturbance Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 241000790234 Sphingomonas elodea Species 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 235000019486 Sunflower oil Nutrition 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• 239000005844 Thymol Substances 0.000 description 1
• 208000004374 Tick Bites Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 208000005448 Trichomonas Infections Diseases 0.000 description 1
• 206010044620 Trichomoniasis Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
• PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
• 241000223105 Trypanosoma brucei Species 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
• ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 229950006790 adenosine phosphate Drugs 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 230000003113 alkalizing effect Effects 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 229920001586 anionic polysaccharide Polymers 0.000 description 1
• 150000004836 anionic polysaccharides Chemical class 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 229940005530 anxiolytics Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 229960000892 attapulgite Drugs 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 230000006736 behavioral deficit Effects 0.000 description 1
• 208000013404 behavioral symptom Diseases 0.000 description 1
• 238000013542 behavioral therapy Methods 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• 229940092782 bentonite Drugs 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229960001716 benzalkonium Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000004397 blinking Effects 0.000 description 1
• 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• 229960002645 boric acid Drugs 0.000 description 1
• 235000010338 boric acid Nutrition 0.000 description 1
• 229960003168 bronopol Drugs 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
• 235000011092 calcium acetate Nutrition 0.000 description 1
• 239000001639 calcium acetate Substances 0.000 description 1
• 229960005147 calcium acetate Drugs 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229960002713 calcium chloride Drugs 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000000828 canola oil Substances 0.000 description 1
• 235000019519 canola oil Nutrition 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940105329 carboxymethylcellulose Drugs 0.000 description 1
• 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 229960001777 castor oil Drugs 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920003086 cellulose ether Polymers 0.000 description 1
• 230000021617 central nervous system development Effects 0.000 description 1
• 229940043431 ceratonia Drugs 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 229940045110 chitosan Drugs 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 229960002242 chlorocresol Drugs 0.000 description 1
• 229960005443 chloroxylenol Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 230000002060 circadian Effects 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 229960002303 citric acid monohydrate Drugs 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229920001531 copovidone Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000009193 crawling Effects 0.000 description 1
• 229930003836 cresol Natural products 0.000 description 1
• 229940013361 cresol Drugs 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 206010052015 cytokine release syndrome Diseases 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 210000001947 dentate gyrus Anatomy 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000005131 dialkylammonium group Chemical group 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 229940008099 dimethicone Drugs 0.000 description 1
• 239000004205 dimethyl polysiloxane Substances 0.000 description 1
• 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
• 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 229960000878 docusate sodium Drugs 0.000 description 1
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
• 235000010386 dodecyl gallate Nutrition 0.000 description 1
• 239000000555 dodecyl gallate Substances 0.000 description 1
• 229940080643 dodecyl gallate Drugs 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• 229960001484 edetic acid Drugs 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 150000002081 enamines Chemical class 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 235000010350 erythorbic acid Nutrition 0.000 description 1
• 239000004318 erythorbic acid Substances 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229960004667 ethyl cellulose Drugs 0.000 description 1
• 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 230000008622 extracellular signaling Effects 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 230000014061 fear response Effects 0.000 description 1
• 210000003811 finger Anatomy 0.000 description 1
• 210000001145 finger joint Anatomy 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 229960002598 fumaric acid Drugs 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000009760 functional impairment Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 201000006592 giardiasis Diseases 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 1
• LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229960004867 hexetidine Drugs 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
• 230000006607 hypermethylation Effects 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
• 229940113174 imidurea Drugs 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000035992 intercellular communication Effects 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 150000002500 ions Chemical group 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229940026239 isoascorbic acid Drugs 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 229960004592 isopropanol Drugs 0.000 description 1
• 229940093629 isopropyl isostearate Drugs 0.000 description 1
• 229940074928 isopropyl myristate Drugs 0.000 description 1
• XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
• 229940075495 isopropyl palmitate Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940033355 lauric acid Drugs 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 231100000516 lung damage Toxicity 0.000 description 1
• 239000000395 magnesium oxide Substances 0.000 description 1
• CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
• 229960000869 magnesium oxide Drugs 0.000 description 1
• 235000012245 magnesium oxide Nutrition 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229940099690 malic acid Drugs 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 229940057917 medium chain triglycerides Drugs 0.000 description 1
• 210000001259 mesencephalon Anatomy 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 208000004141 microcephaly Diseases 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• INMHJULHWVWVFN-UHFFFAOYSA-N naphthalene-1,3,5-trisulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(S(=O)(=O)O)=CC(S(O)(=O)=O)=C21 INMHJULHWVWVFN-UHFFFAOYSA-N 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 208000020470 nervous system symptom Diseases 0.000 description 1
• 230000007230 neural mechanism Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 231100000878 neurological injury Toxicity 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 239000002840 nitric oxide donor Substances 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229940079938 nitrocellulose Drugs 0.000 description 1
• 230000000422 nocturnal effect Effects 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• 238000001584 occupational therapy Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
• 229940066429 octoxynol Drugs 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 235000010387 octyl gallate Nutrition 0.000 description 1
• 239000000574 octyl gallate Substances 0.000 description 1
• NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 210000000196 olfactory nerve Anatomy 0.000 description 1
• 229940109739 orap Drugs 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 239000003346 palm kernel oil Substances 0.000 description 1
• 235000019865 palm kernel oil Nutrition 0.000 description 1
• 229910052625 palygorskite Inorganic materials 0.000 description 1
• 210000003695 paranasal sinus Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 229960003330 pentetic acid Drugs 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 229960005323 phenoxyethanol Drugs 0.000 description 1
• 229940067107 phenylethyl alcohol Drugs 0.000 description 1
• 229940096826 phenylmercuric acetate Drugs 0.000 description 1
• VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
• 229960000247 phenylmercuric borate Drugs 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 229960003634 pimozide Drugs 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
• 235000013856 polydextrose Nutrition 0.000 description 1
• 239000001259 polydextrose Substances 0.000 description 1
• 229940035035 polydextrose Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 235000010235 potassium benzoate Nutrition 0.000 description 1
• 239000004300 potassium benzoate Substances 0.000 description 1
• 229940103091 potassium benzoate Drugs 0.000 description 1
• 235000010333 potassium nitrate Nutrition 0.000 description 1
• 239000004323 potassium nitrate Substances 0.000 description 1
• 229940093928 potassium nitrate Drugs 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000012254 powdered material Substances 0.000 description 1
• 206010036601 premature menopause Diseases 0.000 description 1
• 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960005359 propylparaben sodium Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 238000013138 pruning Methods 0.000 description 1
• 230000008433 psychological processes and functions Effects 0.000 description 1
• 239000002212 purine nucleoside Substances 0.000 description 1
• 239000002213 purine nucleotide Substances 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003214 pyranose derivatives Chemical class 0.000 description 1
• 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
• 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
• 230000009183 running Effects 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000009151 sensory gating Effects 0.000 description 1
• 208000018316 severe headache Diseases 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 230000035943 smell Effects 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229960004249 sodium acetate Drugs 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 229960004599 sodium borate Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
• 235000010334 sodium propionate Nutrition 0.000 description 1
• 239000004324 sodium propionate Substances 0.000 description 1
• 229960003212 sodium propionate Drugs 0.000 description 1
• JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 229940001474 sodium thiosulfate Drugs 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 229960002920 sorbitol Drugs 0.000 description 1
• 238000002630 speech therapy Methods 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000003351 stiffener Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
• 239000002600 sunflower oil Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000003977 synaptic function Effects 0.000 description 1
• 230000007617 synaptic impairment Effects 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 208000006345 telecanthus Diseases 0.000 description 1
• 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
• TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 210000003813 thumb Anatomy 0.000 description 1
• 229960000790 thymol Drugs 0.000 description 1
• 230000003867 tiredness Effects 0.000 description 1
• 208000016255 tiredness Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 229940074410 trehalose Drugs 0.000 description 1
• 125000005208 trialkylammonium group Chemical group 0.000 description 1
• 210000003901 trigeminal nerve Anatomy 0.000 description 1
• PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
• 229940117972 triolein Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960004418 trolamine Drugs 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 208000009421 viral pneumonia Diseases 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• WCJYTPVNMWIZCG-UHFFFAOYSA-N xylylcarb Chemical compound CNC(=O)OC1=CC=C(C)C(C)=C1 WCJYTPVNMWIZCG-UHFFFAOYSA-N 0.000 description 1
• 239000004246 zinc acetate Substances 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 229960001296 zinc oxide Drugs 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1